MEDP
Strong BuyPremium GrowerAI neutralMedpace Holdings, Inc. · Healthcare · United States · $17.2B cap · $142.3M/day traded
$609.89 -1.6% · close 13 Oct · scored 15 Oct
StockRank down 1.0 since 14 Oct.
Premium Grower: Strong business with the market behind it, priced at a premium.
Read our full research report on MEDP (Jun 2026), freeReport expected 19 Oct: the next-year EPS estimate has risen 2.4% over the last 13 weeks.
As of 15 Oct 2026, MoatMap's StockRank for Medpace Holdings, Inc. (MEDP) is 82/100, ranked against 24,000+ stocks in 35 markets (Quality 84, Value 26, Momentum 69, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Medpace runs clinical trials for small and mid-sized biotech companies. It has industry-leading margins and returns on capital, and it has a long record of buying back its own shares. Second-quarter results showed strong revenue growth and record figures. Against that, insiders sold 0.87% of the shares over 90 days, a steady run of Form 4 filings, and the company's client base depends on biotech funding, which tends to tighten when rates stay high. The quality is real, but the timing is not compelling enough to call.
ABOUT MEDPACE HOLDINGS, INC.
Read
Medpace Holdings, Inc. is a global, full-service clinical contract research organization (CRO) providing clinical development services to biopharmaceutical and medical device companies. The company specializes in scientifically-driven clinical trials, particularly for small to mid-sized biopharma firms, offering a comprehensive and integrated approach. Its deep therapeutic expertise, operational efficiency, and focus on complex, high-quality trials provide a strong competitive moat within the specialized CRO market.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.5B | 1.9B | 2.1B | 2.5B | 20.1% | 2.8B | 2.9B | 3.0B | 9.5% |
| EPS | 5.06 | 7.57 | 9.20 | 13.06 | 15.64 | 32.6% | 17.03 | 18.13 | 19.77 | 12.4% |
| Shares | — | 31.1M | 30.8M | 30.6M | 28.4M | -8.8% | 27.9M | — | — | — |
| Debt | — | 188.9M | 142.1M | 126.2M | 113.6M | -15.6% | 144.1M | — | — | — |
| Equity | — | 386.4M | 559.0M | 825.5M | 459.1M | 5.9% | — | — | — | — |
| Op CF | — | 388.1M | 433.4M | 608.8M | 713.2M | 22.5% | 752.7M | — | — | — |
| Inv CF | — | -38.7M | -34.6M | -28.3M | -31.1M | — | — | — | — | — |
| Fin CF | — | -775.8M | -182.6M | -154.0M | -860.4M | — | — | — | — | — |
Above its 200-day average and 10% below its 52-week high.
Swung more than 55% of stocks we rank over the past year (44% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MEDP are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MEDP | Medpace Holdings, Inc.(you) | $17.2B | 82 | Strong Buy |
| LH | Labcorp Holdings Inc. | $24.7B | 83 | Strong Buy |
| DGX | Quest Diagnostics Incorporated | $25.7B | 81 | Strong Buy |
| ILU.DE | Illumina, Inc. | $40.7B | 83 | Strong Buy |
| A1GI34.SA | Agilent Technologies, Inc. | $48.1B | 84 | Strong Buy |
| RVTY | Revvity, Inc. | $15.9B | 60 | Hold |
| CRL | Charles River Laboratories International, Inc. | $13.4B | 63 | Hold |
| SHC | Sotera Health Company | $5.2B | 80 | Strong Buy |
| IQV | IQVIA Holdings Inc. | $44.1B | 71 | Buy |
| WAT | Waters Corporation | $41.3B | 61 | Hold |
Peer medians: ROE -26.1% · P/E 28.5x · Gross margin 64.2%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.